# An Initial Evaluation of AN8025 in Solid Tumors

> **NCT07639047** · PHASE1 · RECRUITING · sponsor: **Adlai Nortye Biopharma Co., Ltd.** · enrollment: 91 (estimated)

## Conditions studied

- Advanced Solid Tumor (Phase 1)

## Interventions

- **DRUG:** AN8025 is a multifunctional antibody fusion protein

## Key facts

- **NCT ID:** NCT07639047
- **Lead sponsor:** Adlai Nortye Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-07
- **Final completion:** 2028-01
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639047, "An Initial Evaluation of AN8025 in Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07639047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*